CD59 has previously been detected in blood plasma (Yan et al., 2019) and urine EVs (Lu et al., 2009) from prostate cancer patients, as well as in blood plasma EVs from colorectal cancer patients (Dash et al., 2022), suggesting that CD59 is predominantly an EV cargo protein associated with later stages of cancer. This evidence concerns the gene CD59 and prostate carcinoma.